Showing results (1-10 of 34) with videos related to
Sort By:
Pageof 4
Biochimica Et Biophysica Acta|December 21, 2014
Cerebrospinal fluid proteomics and protein biomarkers in frontotemporal lobar degeneration: Current status and future perspectivesPatrick Oeckl, Petra Steinacker, Emily Feneberg, et al.Journal of Neurochemistry|May 18, 2016
Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an updatePatrick Oeckl, Petra Steinacker, Emily Feneberg, et al.Der Nervenarzt|April 17, 2024
[Smell the smoke before one sees the fire-The oligosymptomatic prodromal phase of neurodegenerative diseases]Andreas Wolff, Antonia Franziska Demleitner, Emily Feneberg, et al.Journal of Neural Transmission (Vienna, Austria : 1996)|April 18, 2022
SARS-CoV-2 and neurodegenerative diseases: what we know and what we don'tPaul Lingor, Antonia F Demleitner, Andreas W Wolff, et al.Molecular Neurobiology|February 21, 2018
Towards a TDP-43-Based Biomarker for ALS and FTLDEmily Feneberg, Elizabeth Gray, Olaf Ansorge, et al.Sleep Medicine|June 11, 2013
Elevated glial fibrillary acidic protein levels in the cerebrospinal fluid of patients with narcolepsyEmily Feneberg, Petra Steinacker, Stefan Lehnert, et al.Journal of Neurology|July 29, 2018
Amyotrophic lateral sclerosis: the complex path to precision medicineKevin Talbot, Emily Feneberg, Jakub Scaber, et al.Frontiers in Neuroanatomy|August 6, 2019
Hibernation Impairs Odor Discrimination - Implications for Alzheimer's DiseaseTorsten Bullmann, Emily Feneberg, Tanja Petra Kretzschmann, et al.Cells|February 25, 2023
TDP-43 Proteinopathy Specific Biomarker DevelopmentIsabell Cordts, Annika Wachinger, Carlo Scialo, et al.Expert Review of Proteomics|November 11, 2021
Advancing mechanistic understanding and biomarker development in amyotrophic lateral sclerosisAlexander G Thompson, Patrick Oeckl, Emily Feneberg, et al.Pageof 4